Every 8-K that Kintara Therapeutics, Inc. (KTRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KTRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KTRA filings page.
TuHURA Biosciences, Inc. reports that it has advanced its previously announced private placement by securing immediate purchases of approximately $3.2 million from certain investors who had deferred part of their commitment. These investors were originally obligated to buy a remaining portion of a $3.7 million final tranche under a June 2, 2025 securities purchase agreement tied to a larger $12.6 million offering of common stock and warrants.
In return for accelerating the purchase of this final tranche amount, TuHURA agreed to amend existing warrants issued in a 2024 private placement of convertible notes. The company extended the expiration dates of warrants to purchase an aggregate of 1.5 million shares of common stock, moving their expiry out to December 31, 2030. The detailed terms are set out in the final closing and warrant amendment agreements referenced in the report.
TuHURA Biosciences, Inc. filed a current report to furnish a press release that outlines its financial results for the three months ended June 30, 2025 and provides a corporate update. The press release, dated August 14, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report on a furnished, not filed, basis under securities laws. TuHURA’s common stock, with a par value of $0.001 per share, trades on the Nasdaq Capital Market under the symbol HURA.
TuHURA Biosciences completed the acquisition of Kineta, Inc. on June 30, 2025 under the Agreement and Plan of Merger dated December 11, 2024, as amended May 5, 2025. The transaction was structured as a two-step series of mergers: Merger Sub I merged into Kineta (the Surviving Entity), which then merged into Merger Sub II, with Merger Sub II surviving.
This Form 8-K/A amends TuHURA’s original June 30, 2025 report to furnish Item 9.01 financial disclosures. The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1 and provides unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2, including a pro forma balance sheet and statements of operations on the noted dates and periods. The filing notes substantially the same financial statements were previously included in TuHURA’s Form S-4, declared effective May 14, 2025. The amendment is signed by CFO Dan Dearborn.